Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan.

Slides:



Advertisements
Similar presentations
Chapter 17 Coagulation Testing
Advertisements

Robert C. Gorman, MDa(by invitation), Nicholas P
Peter E. Ballmer, MDa, Walter H
Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,
Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model  Paul M. Petre, MDa, Frank A. Baciewicz, MDb, Stefan.
Activated Partial Thromboplastin Time (aPTT)
Yuji Hiramatsu, MDa, Nicolas Gikakis, BSEa, Harry L
Sally Bannan, Amanda Danby, Dahlia Cowan, Saeed Ashraf, Paul G Martin 
Reopro removal during cardiopulmonary bypass using a hemoconcentrator
Ex vivo lung model of pig-to-human hyperacute xenograft rejection
Keloid Fibroblasts Resist Ceramide-Induced Apoptosis by Overexpression of Insulin- Like Growth Factor I Receptor  Hiroshi Ishihara, Hiroshi Yoshimoto,
Rohun U. Palekar, BS, Chandu Vemuri, MD, Jon N
Jacek M. Karski, MDa, Sally J
Peter E. Ballmer, MDa, Walter H
Baiya Krishnadasan, MD, Babu V
Prostaglandin E2 control of T cell cytokine production is functionally related to the reduced lymphocyte proliferation in atopic dermatitis  Sai Chan,
Preformed confluent endothelial cell monolayers prevent early platelet deposition on vascular prostheses in baboons  Peter A. Schneider, MD, Stephen R.
Tumor necrosis factor-α production in whole blood after cardiopulmonary bypass: Downregulation caused by circulating cytokine-inhibitory activities  J.
Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary.
Does steroid pretreatment increase endotoxin release during clinical cardiopulmonary bypass?  Song Wan, MD, PhDa, Jean-Louis LeClerc, MDb, Chi-Hoang Huynh,
Richard J. Kaplon, MDa, Mehmet C. Oz, MDa, Pawel A
Time-dependent cellular population of textured-surface left ventricular assist devices contributes to the development of a biphasic systemic procoagulant.
Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model  Paul M. Petre, MDa, Frank A. Baciewicz, MDb, Stefan.
P. W. Boonstra, MD, PhD, Y. J. Gu, MD, PhD, C. Akkerman, BSc, J
Enhancement of the leukocyte–endothelial cell interaction in collecting venules of skeletal muscle by protamine  Helmut Habazettl, MDa, Vladimir Martinek,
M. Griese, MD, C. Wilnhammer, MD, S. Jansen *, C. Rinker, MD 
Oz M. Shapira, MDa, Aiming Xu, PhDb, Joseph A. Vita, MDb, Gabriel S
The effects of carmeda bioactive surface on human blood components during simulated extracorporeal circulation  Robert L. Korn, MD, PhD, Carol A. Fisher,
Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation  G.J. Despotis, MDa, S.A. Santoro,
The influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function: A clinical study  Tomislav Mihaljevic, MDa, Martin.
Reduction of bleeding after heart operations through the prophylactic use of epsilon- aminocaproic acid  Thomas J. Vander Salm, MDa, Shubjeet Kaur, MDb,
Ischemia and activated neutrophils alter coronary microvascular but not epicardial coronary artery reactivity  Margit Kadletz, MDa, Rebecca J. Dignan,
Glucocorticoids inhibit IL-4 and mitogen-induced IL-4Rα chain expression by different posttranscriptional mechanisms  Lourdes Mozo, PhDa, Abel Gayo, BSa,
Neuronal Nitric Oxide Synthase Inhibition Reduces Neuronal Apoptosis After Hypothermic Circulatory Arrest  Elaine E Tseng, Malcolm V Brock, Mary S Lange,
The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass  Elijah W. Muriithi,
Reversal of heparin anticoagulation by recombinant platelet factor 4 and protamine sulfate in baboons during cardiopulmonary bypass  Alvise Bernabei,
Biocompatibility of heparin-coated extracorporeal bypass circuits: A randomized, masked clinical trial  Derek D. Muehrcke, MDa, Patrick M. McCarthy, MDa,
Intraoperative autotransfusion in aortic surgery: Comparison of whole blood autotransfusion versus cell separation  Claus Bartels, MD, J.V. Matthias Bechtel,
Anne H Kuitunen, MD, Lasse J Heikkilä, MD, Markku T Salmenperä, MD 
Richard J. Novick, MDa, Ruud A. W
Hermann Reichenspurner, MD, PhD, Jose A
Effects of thrombolysis and venous thrombectomy on valvular competence, thrombogenicity, venous wall morphology, and function  Jae-Sung Cho, MD, Eugenio.
Whole blood heparin concentration measurements by automated protamine titration agree with plasma anti-Xa measurements  G.J. Despotis, MD, J.H. Joist,
Platelet-leukocyte activation and modulation of adhesion receptors in pediatric patients with congenital heart disease undergoing cardiopulmonary bypass 
Cerebral hyperthermia during cardiopulmonary bypass in adults
Complement and granulocyte activation in two different types of heparinized extracorporeal circuits  Eivind Øvrum, MDa, Tom Eirik Mollnes, MD, PhDb, Erik.
Chemokines induce eosinophil degranulation through CCR-3
Modified Ultrafiltration Versus Conventional Ultrafiltration: A Randomized Prospective Study In Neonatal Piglets  C.William Daggett, MD, Andrew J. Lodge,
Evidence of human non-α-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion  Paolo Macchiarini,
Kai Ihnken, MD  The Journal of Thoracic and Cardiovascular Surgery 
Individualized heparin and protamine management in infants and children undergoing cardiac operations  Massimiliano Codispoti, MD, Christopher A Ludlam,
Gut mucosal ischemia during normothermic cardiopulmonary bypass results from blood flow redistribution and increased oxygen demand  Weike Tao, MDa, Joseph.
Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study  Joseph B Zwischenberger, MD, Weike Tao, MD, Donald.
Aspirin resistance after coronary artery bypass grafting
The limits of detectable cerebral perfusion by transcranial doppler sonography in neonates undergoing deep hypothermic low-flow cardiopulmonary bypass 
Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution  Raymond G. Makhoul, M.D., Charles S. Greenberg,
Early markers of major adverse events in children after cardiac operations  Trevor Duke, FRACPa, Warwick Butt, FRACPa, Mike South, MD, FRACPb, Tom R. Karl,
Postbypass effects of delayed rewarming on cerebral blood flow velocities in infants after total circulatory arrest  Rosendo A. Rodriguez, MD, PhDa (by.
Qianli Zhuang, MD, PhD, Bruce Mazer, MD 
Effect of Nitric Oxide Gas on Platelets During Open Heart Operations
Sequence-dependent enhancement of paclitaxel toxicity in non–small cell lung cancer by 17-allylamino 17-demethoxygeldanamycin  Dao M. Nguyen, MD, FRCSC,
Goya V. Raikar, MD, Kunikazu Hisamochi, MD, Bao-Lan N
Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery  William C Oliver, MD, David N Fass, PhD, Gregory A Nuttall,
Myocardium is a major source of proinflammatory cytokines in patients undergoing cardiopulmonary bypass  Song Wan, MDa, Jean-Marie DeSmet, MDa, Luc Barvais,
Jay E. Slater, MDa, Elizabeth J. Paupore, BSa, Michael R
William L. Holman, MDa, Russell D. Spruell, BSEEa, Edward R
Influence of High- and Low-Dose Aprotinin on Activation of Hemostasis in Open Heart Operations  Wulf Dietrich, Karl Schöpf, Michael Spannagl, Marianne.
Y.John Gu, MD, PhD, Piet W. Boonstra, MD, PhD, Willem van Oeveren, PhD 
A randomized trial of antithrombin concentrate for treatment of heparin resistance  Mathew R Williams, MD, Alyssa B D’Ambra, BA, James R Beck, Talia B.
Thrombophilic Variables Do Not Increase the Generation or Procoagulant Activity of Thrombin During Cardiopulmonary Bypass  Peter Raivio, MD, Jari Petäjä,
Presentation transcript:

Heparinless cardiopulmonary bypass with active-site blocked factor IXa: A preliminary study on the dog  Talia B. Spanier, MDa, Mehmet C. Oz, MDa, Oktavijan P. Minanov, MDa, Ronit Simantov, MDe, Walter Kisiel, PhDd, David M. Stern, MDa,b, Eric A. Rose, MDa, Ann Marie Schmidt, MDa,c  The Journal of Thoracic and Cardiovascular Surgery  Volume 115, Issue 5, Pages 1179-1188 (May 1998) DOI: 10.1016/S0022-5223(98)70419-2 Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 1 MCCT. A, Assay procedure. Factor IX-deficient plasma was incubated with Celite (0.024 mol/L in barbital buffer [0.05 mol/L]) in silicone-coated glass tubes for 2 minutes in a shaking water bath at 37° C. An optimized concentration of cephalin (1:32; B) in barbital buffer (0.05 mol/L) was added, along with control or test-dog plasma (0.05 ml) and calcium chloride (0.001 mol/L). Time to clot formation was then visually determined. C, Determination of the limit of detection of the MCCT was performed with different concentrations of IXai and normal dog plasma. Data were plotted as log MCCT versus log [IXai] of each value. The limit of detection in this assay is 0.06 μg/ml. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 2 Purification of factor IXai from Proplex. Factor IX was purified from Proplex and activated with factor XIa as described. IXa was then reacted with dansyl-Glu-Gly-Arg-chloromethylketone to yield IXai. Factors IX, IXa, and IXai were run on SDS-PAGE under nonreducing or reducing conditions as indicated: Lane 1 (10 μg); lane 2 (10 μg); lane 3 (10 μg); lane 4 (15 μg); lane 5 (10 μg); and lane 6 (15 μg). The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 3 Scanning electron microscopy of the CPB filters. Dogs were treated with IXai (460 μg/kg) or heparin (300 IU/kg/protamine 2 mg/kg) and underwent CPB for 1 hour. At the end of CPB, the filters were removed and subjected to scanning electron microscopy at the indicated magnifications. CPB performed with IXai (460 μg/kg) was associated with similar amounts of clinically inapparent fibrin deposition, compared with heparin (left panel). At 360 μg/kg IXai, visible fibrin and platelet deposition was observed (right panel). The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 4 Thoracic-cavity blood loss in dogs undergoing CPB. Dogs underwent CPB with either IXai (300 to 600 μg/kg) or heparin/protamine for 1 hour; dogs were then observed for 3 hours after discontinuation of CPB. At the end of the observation period, dogs receiving heparin accumulated 1275 ± 115 ml blood in the thoracic cavity; those dogs receiving either 360 μg/kg or 460 μg/kg IXai accumulated significantly less blood in the thoracic cavity (530  ± 55 ml and 520 ± 30 ml, respectively). At 600 μ/kg IXai, increased bleeding was observed in the thoracic cavity (950 ± 300 ml). *Indicates p < 0.05 in dogs treated with IXai compared with heparin by analysis of variance. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 5 Incisional wound model. To establish the effects of IXai on bleeding outside the operative field, a standardized incisional model in the abdomen was used as described earlier. At an effective antithrombotic dose of IXai (460 μg/kg), there was no evidence of enhanced bleeding at the time points assessed compared to baseline. In contrast, significantly increased bleeding was observed after infusion of heparin during CPB, which returned to baseline after heparin reversal with protamine. At a dose of IXai of 600 μg/kg, significantly increased bleeding was observed during CPB, comparable to that seen with heparin treatment. Data are reported as means ± standard error. *Indicates p < 0.05 in dogs treated with IXai compared with heparin by analysis of variance. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 6 Hematologic analysis. Dogs underwent CPB with either IXai (460 μg/kg) or heparin/protamine. At the indicated times, blood was withdrawn for analysis of white blood cell count (A), hematocrit value (B), and platelets (C). No significant differences were observed between groups. Each group represents mean values observed in four dogs. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 6, cont'd. D, Platelet aggregation studies as described were performed on platelet-rich plasma from normal volunteers in response to epinephrine (100 μm) in the presence of various concentrations of IXai: lane 1, 5.0 μg/ml; lane 2, 1.0 μg/ml; lane 3, 0.8 μg/ml; lane 4, 0.4 μg/ml; lane 5, 0.2 μg/ml; and lane 6, 0.1 μg/ml; or in the presence of IXai/heparin: lane 7, IXai 0.4 μg/ml/heparin 9 U/ml; or heparin alone: lane 8, 13.5 U/ml; and lane 9, 9 U/ml. Arrow indicates the point at which the agonist (epinephrine) was added. In all cases, primary and secondary waves of aggregation were normal. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 7 Analysis of (A) prothrombin time (PT), (B) activated partial thromboplastin time (PTT), and (C)ACT in dogs undergoing CPB. Blood was withdrawn at the indicated times, and citrated plasma was prepared. PT remained control in dogs treated with IXai (460 μg/kg) and activated PTT was mildly elevated. In contrast, dogs treated with heparin/protamine demonstrated significant elevations of PT and activated PTT. ACT values (117 ± 32.0 seconds at baseline in all dogs), which returned to baseline after the administration of protamine, rose to >480 seconds during CPB in the dogs treated with heparin. In contrast, in dogs treated with IXai (460 μg/kg), ACT did not rise significantly above baseline (133 ± 23.0 seconds). *Indicates p < 0.05 in dogs treated with IXai compared with heparin by analysis of variance. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions

Fig. 8 Determination of the MCCT in CPB. Dogs were placed on CPB with an effective antithrombotic dose of IXai (460 μg/kg), and MCCT was measured throughout the procedure. Baseline (preoperative) MCCT was 21 ± 1.2 seconds, which rose to 80 seconds after administration of IXai. Levels returned to baseline by 3 hours after CPB. Similarly, dogs were placed on bypass with heparin and reversed after bypass with protamine. The Journal of Thoracic and Cardiovascular Surgery 1998 115, 1179-1188DOI: (10.1016/S0022-5223(98)70419-2) Copyright © 1998 Mosby, Inc. Terms and Conditions